Skip to Content

Insulin glargine / lixisenatide Disease Interactions

There are 7 disease interactions with insulin glargine / lixisenatide:

Major

Lixisenatide (Includes insulin glargine/lixisenatide) ↔ angioedema

Severe Potential Hazard, Moderate plausibility. Applies to: Angioedema, Anaphylaxis

The use of lixisenatide may result in cross-sensitivity in patients with a history of anaphylaxis reaction or angioedema to another GLP-1 receptor agonist. These patients should be informed of the risk of anaphylaxis when using lixisenatide. Close monitoring is recommended when prescribing lixisenatide to these patients.

Major

Lixisenatide (Includes insulin glargine/lixisenatide) ↔ gastroparesis

Severe Potential Hazard, Moderate plausibility. Applies to: Gastroparesis

Lixisenatide slows gastric emptying and patients with preexisting gastroparesis were excluded from clinical trials. Lixisenatide should not be used in patients with severe gastroparesis.

Major

Lixisenatide (Includes insulin glargine/lixisenatide) ↔ pancreatitis

Severe Potential Hazard, Moderate plausibility. Applies to: Pancreatitis, Cholelithiasis, Alcoholism

Acute pancreatitis, including fatal and non- fatal hemorrhagic or necrotizing pancreatitis, has been reported postmarketing in patients treated with lixisenatide. Some patients had risk factors such as cholelithiasis and alcohol abuse. Patients should be observed carefully for any symptoms of pancreatitis including persistent abdominal pain, sometimes radiating to the back, that may or may not be accompanied by vomiting. If pancreatitis is suspected, lixisenatide should be discontinued and appropriate management should be established. If pancreatitis is confirmed, lixisenatide should not be restarted. Lixisenatide is not recommended for patients with history of pancreatitis.

Moderate

Insulin (Includes insulin glargine/lixisenatide) ↔ renal/liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Liver Disease

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References

  1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  2. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  3. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Insulin- hypokalemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypokalemia

Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

Moderate

Insulin/oral hypoglycemic agents (Includes insulin glargine/lixisenatide) ↔ hypoglycemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems

Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.

References

  1. "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  3. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  4. "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.
  5. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  6. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  7. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  8. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  9. "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.
  10. "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  11. "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.
  12. "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.
  14. "Multum Information Services, Inc. Expert Review Panel"
  15. "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.
View all 15 references
Moderate

Lixisenatide (Includes insulin glargine/lixisenatide) ↔ end stage renal disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Acute kidney injury and worsening of chronic renal failure which sometimes required hemodialysis has been reported postmarketing in patients treated with lixisenatide. Renal function should be closely monitored when initiating or escalating doses. Lixisenatide is not recommended for patients with end stage renal disease. Patients with mild and moderate renal impairment need close monitoring but no dose adjustment. There is limited experience in patients with severe renal impairment but drug exposure showed to be higher, so close monitoring is recommended for changes in renal function or gastrointestinal adverse reactions.

Insulin glargine / lixisenatide drug interactions

There are 897 drug interactions with insulin glargine / lixisenatide

Insulin glargine / lixisenatide alcohol/food interactions

There are 2 alcohol/food interactions with insulin glargine / lixisenatide

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide